Cogent Biosciences, Inc. (COGT) stock
COGTNasdaqPharmaceutical PreparationsFiscal year ends December 31
$27.85+0.41 (+1.49%)
Close on Nov 17, 2026Market cap $4.83BP/E –Yield –
Cogent Biosciences total assets
Total assets on the balance sheet at the end of each period.
Cogent Biosciences's total assets was $834.55M at Jun 30, 2026. For fiscal 2025 it was $937.61M, up 185.9% from the year before. The highest annual figure on record is $937.61M in fiscal 2025.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $937.61M | +185.9% |
| FY2024 | Dec 31, 2024 | $327.90M | +4.6% |
| FY2023 | Dec 31, 2023 | $313.44M | +4.2% |
| FY2022 | Dec 31, 2022 | $300.81M | +29.6% |
| FY2021 | Dec 31, 2021 | $232.09M | -7.5% |
| FY2020 | Dec 31, 2020 | $250.92M | +407.7% |
| FY2019 | Dec 31, 2019 | $49.42M | -42.5% |
| FY2018 | Dec 31, 2018 | $85.93M | +75.0% |
| FY2017 | Dec 31, 2017 | $49.12M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $834.55M | +203.7% |
| Q1 FY2026 | Mar 31, 2026 | $903.01M | +218.2% |
| Q4 FY2025 | Dec 31, 2025 | $937.61M | +185.9% |
| Q3 FY2025 | Sep 30, 2025 | $425.93M | +10.9% |
| Q2 FY2025 | Jun 30, 2025 | $274.82M | -36.1% |
| Q1 FY2025 | Mar 31, 2025 | $283.80M | -40.4% |
| Q4 FY2024 | Dec 31, 2024 | $327.90M | +4.6% |
| Q3 FY2024 | Sep 30, 2024 | $384.02M | +8.0% |
| Q2 FY2024 | Jun 30, 2024 | $429.94M | +9.6% |
| Q1 FY2024 | Mar 31, 2024 | $476.11M | +80.9% |
| Q4 FY2023 | Dec 31, 2023 | $313.44M | +4.2% |
| Q3 FY2023 | Sep 30, 2023 | $355.45M | +7.2% |
| Q2 FY2023 | Jun 30, 2023 | $392.37M | +7.2% |
| Q1 FY2023 | Mar 31, 2023 | $263.20M | +27.2% |
| Q4 FY2022 | Dec 31, 2022 | $300.81M | +29.6% |
| Q3 FY2022 | Sep 30, 2022 | $331.56M | +53.9% |
| Q2 FY2022 | Jun 30, 2022 | $366.05M | +60.2% |
| Q1 FY2022 | Mar 31, 2022 | $206.87M | -12.9% |
| Q4 FY2021 | Dec 31, 2021 | $232.09M | -7.5% |
| Q3 FY2021 | Sep 30, 2021 | $215.39M | +54.0% |
| Q2 FY2021 | Jun 30, 2021 | $228.52M | +635.8% |
| Q1 FY2021 | Mar 31, 2021 | $237.61M | +510.2% |
| Q4 FY2020 | Dec 31, 2020 | $250.92M | +407.7% |
| Q3 FY2020 | Sep 30, 2020 | $139.87M | +141.6% |
| Q2 FY2020 | Jun 30, 2020 | $31.06M | -55.2% |
| Q1 FY2020 | Mar 31, 2020 | $38.94M | -52.1% |
| Q4 FY2019 | Dec 31, 2019 | $49.42M | -42.5% |
| Q3 FY2019 | Sep 30, 2019 | $57.88M | -38.9% |
| Q2 FY2019 | Jun 30, 2019 | $69.31M | -32.5% |
| Q1 FY2019 | Mar 31, 2019 | $81.28M | +87.2% |
| Q4 FY2018 | Dec 31, 2018 | $85.93M | +75.0% |
| Q3 FY2018 | Sep 30, 2018 | $94.79M | – |
| Q2 FY2018 | Jun 30, 2018 | $102.72M | – |
| Q1 FY2018 | Mar 31, 2018 | $43.42M | – |
| Q4 FY2017 | Dec 31, 2017 | $49.12M | – |
See a number that looks wrong?